Fangsheng Pharmaceutical: A subsidiary holding company's traditional Chinese medicine innovative drug research and development project has received the drug clinical trial approval notification.

Fang Sheng Pharmaceutical announced that its holding subsidiary Fang Sheng Rongke Traditional Chinese Medicine Innovative Drug Development Project has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Ziying Granules. Ziying Granules is a Type 1.1 innovative traditional Chinese medicine independently developed by Fang Sheng Rongke, which has not yet been launched in domestic and international markets as of the date of this announcement. This product is based on years of clinical experience in the treatment of pelvic inflammatory disease. It is used for the sequelae of pelvic inflammatory diseases, specifically chronic pelvic pain, with symptoms including lower abdominal dull pain, lumbar sacral distending pain, increased vaginal discharge, thick yellow discharge, low-grade fever, worsened abdominal pain during menstruation, chest tightness, poor appetite, dry mouth, loose stools or constipation, and dark yellow urine.